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Introduction
The human β -adrenoceptor ( β ADR) is a member of the family of seven-transmembrane G-protein-coupled receptors, encoded by a gene on chromosome 5 ( 1 ) . Previous studies have shown that sympathetic nervous activity via β ADRs regulates numerous physiological events and modulates a wide range of physiological responses, including cardiac chronotropy and inotropy, vascular and smooth muscle tone, carbohydrate and lipid metabolism ( 2 ) . Sympathetic nervous activity plays an important role in the development of hyper-tension and its complications ( 3 ) . Three isotypes of human β ADRs, β 1 , β 2 , and β 3 , are involved in this system. The classical subdivision of β ADRs defines β 1 as the subtype that stimulates cardiac muscle ( 4 ) and β 2 as the subtype that relaxes smooth muscle ( 5 ) . The expression of the β 3 subtype is essentially limited to adipose tissue ( 6 ) .
Genetic polymorphisms may influence the development of disease states ( 7 ) . Diseases such as hypertension could be based on genetic disorders as well as environmental factors, or may occur as a secondary product of either cardiac events such as left ventricular hypertrophy (LVH) and arterial stiffness, or interactions among them ( 8 ) . LVH has been considered to be an intermediate phenotype of hypertensive heart diseases ( 9 ) . Recently arterial stiffness was suggested to be an independent predictor of the presence of coronary artery disease ( 10 ) , and arterial stiffness was associated with LVH in hemodialysis patients ( 11 ) . Therefore, arterial stiffness was considered to be an intermediate phenotype of hypertensive complications. A number of single nucleotide polymorphisms (SNPs) of β ADR subtypes have recently been reported to be positional candidate genes for cardiovascular diseases ( 12 , 13 ) . For instance, the genotype of the Arg389Gly polymorphism in the human β 1 -adrenoceptor ( β 1 ADR) gene is reported to be associated with acute myocardial infarction ( 14 ) and hypertensive status ( 15 ) , an association study ( 16 ) suggested that the gene encoding the β 2 -adrenoceptor ( β 2 ADR) was associated with essential hypertension; and the Arg64 allele of the β 3 -adrenoceptor ( β 3 ADR) gene is associated with obesity-related phenotypes ( 17 ) , insulin resistance, hypertension, coronary artery disease and earlier age of onset of diabetes ( 18 ) . The essential effects of the three β ADRs, however, need to be further clarified.
The aim of the present hospital-based observational study was to investigate potential genetic relationships between the β ADR SNPs that result in amino acid substitutions and the cardiovascular risk factors of hypertension, such as LVH and aortic stiffness. We focused on five representative β -adrenoceptor SNPs in patients with essential hypertension.
Methods

Study Population
The present clinical study was designed as a hospital-based and cross-sectional study. We identified 331 Osaka University Medical Hospital patients with essential hypertension. Hypertension was defined as systolic blood pressure (SBP) of more than 140 mmHg and/or diastolic blood pressure (DBP) of more than 90 mmHg and/or administration of antihypertensive drugs. Twelve patients were excluded because of atrial fibrillation and/or frequent ventricular premature beats (more than 5% of the day), and we excluded nine patients whose echocardiography could not be evaluated. Four patients refused to undergo venepuncture. We also excluded six patients in whom we failed to detect the five target SNPs. Finally, 300 patients with essential hypertension for whom the target SNPs could be detected were enrolled. We diagnosed essential hypertension as defined above. The protocol of this study was approved by the hospital ethics committee (permission number: 80) and written informed consent was obtained from all participants. For this study, 115 patients not receiving antihypertensive drug treatment were included. The remaining 185 patients were treated with one or more antihypertensive drugs as follows: 128 patients with a calcium antagonist, 62 patients with an angiotensin receptor blocker, 47 patients with an angiotensin-converting enzyme (ACE) inhibitor, 37 patients with a β -blocker, 25 patients with a diuretic and 10 patients with an α -blocker.
Genotyping
Total genomic DNA was extracted from leukocytes obtained from samples of whole blood, following the standard techniques. In this study, the TaqMan PCR assay as described previously ( 19 ) was used to perform polymorphisms analysis of the three β ADRs, β 1 , β 2 and β 3 ( 20 ) . We detected two poly- In each probe, the polymorphic nucleotide is underlined.
morphisms of β 1 ADR that result in serine/glycine (Ser49Gly) and arginine/glycine (Arg389Gly) amino acid substitutions at residues 49 and 389, respectively. We also detected two polymorphisms of β 2 ADR that result in glycine/arginine (Gly16Arg) and glutamate/glutamine (Glu27Gln) amino acid substitutions at residues 16 and 27, respectively. Finally, we identified a polymorphism in the β 3 ADR that results in a tryptophan/arginine (Trp64Arg) amino acid substitution at residue 64. The primers and probes for the five representative SNPs are shown in Table 1 .
Arterial Functional Changes
We non-invasively evaluated pulse wave velocity (PWV) and vasodilator response to hyperemia as arterial functional changes. PWV was measured using a model FCP-4731 (Fukuda Denshi Co., Tokyo, Japan), which allowed on-line pulse wave recording and automatic calculation as previously reported ( 21 , 22 ) , and the details of this procedure have been reported previously ( 23 ) . The intra-observer coefficient of variation was 2.8 ± 1.2%. We measured the post-ischemic vasodilator response to reactive hyperemia by strain-gauge plethysmography (EC5R; DE Horkkanson, Inc., Bellevue, USA), using a previously published protocol ( 24 ) . To calculate the reactive hyperemia/baseline value of forearm blood flow, we used the reactive hyperemia ratio, and we used the nitroglycerin (NTG)-induced hyperemia ratio as the NTGinduced hyperemia/baseline value. The intra-observer coefficient of variation was 3.4 ± 1.4%.
Cardiac Remodeling
To evaluate cardiac remodeling, we estimated LVH by electrocardiography and echocardiography, and also estimated cardiac enlargement using the cardio-thoracic-ratio (CTR) obtained from chest X-rays. Electrocardiographic LVH 
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Gly (ECGLVH) was determined by Sokolow-Lyon's criteria as the depth of SV1 plus RV5 (mV) (25) . Left ventricular mass index (LVMI) was calculated by echocardiography following Devereux's methods (26) . Additionally, CTR from chest Xrays was calculated as the directly measured ratio of the width of the heart to the thorax width.
Statistical Analysis
Data were analyzed using JMP ver. 4 (SAS Inc., Cary, USA) and presented as the mean±SEM. ANOVA and Student's ttest were used to test for significant differences among the SNPs. A value of p< 0.05 was regarded as statistically significant.
Results
Participant characteristics stratified by genotypes are presented in Table 2 . With respect to the Gly16Arg β2ADR polymorphism, SBP in patients with the Gly16Gly or Gly16Arg polymorphism was significantly lower than that of patients with the Arg16Arg polymorphism. With respect to the Trp64Arg β3ADR polymorphism, the body mass index of patients with the Arg64Arg or Trp64Arg polymorphism was significantly higher than that of patients carrying other genotypes.
The relationship between βADR polymorphisms and arterial functional changes is shown in Table 3 . We evaluated three different parameters for arterial changes, the carotidfemoral PWV as an index of aortic stiffness, reactive hyperemia as an index of post-ischemic vasodilatation to reactive hyperemia, and NTG-induced hyperemia as an index of endothelium-independent vasodilatation. PWV in patients with the Gly49Gly genotype of the β1ADR polymorphism was significantly elevated compared to that of patients with other genotypes (p< 0.05). In the patients with the Gly49Gly genotype, NTG-induced hyperemia was significantly lower compared to that of patients with other genotypes; however, reactive hyperemia showed no significant differences compared to the β1ADR Ser49Gly polymorphism. Reactive hyperemia in patients with the Glu27Gln genotype of the β2ADR polymorphism was significantly lower compared to that of patients with Gln27Gln genotype. Our results for the LVMI, ECGLVH and CTR measurements are also shown in Table 3 . In patients with the Gly/Gly genotype of the β1ADR Ser49Gly polymorphism, CTR was significantly higher compared to the CTRs of patients with other genotypes. In patients with the Glu27Gln genotype of the β2ADR polymorphism, both ECGLVH and LVMI were significantly higher compared to these measures in patients with the Gln27Gln genotype.
To evaluate genetic cooperation between β1ADR Ser49Gly polymorphism and β2ADR Glu27Gln polymorphism, we analyzed the combined influences of these two polymorphisms on arterial and cardiac phenotypes (Table 4 ). Although the numbers of patients with Ser49Gly/Glu27Gln and Gly49Gly/ Gln27Gln were very small (n= 7), patients with Gly49Gly/ Gln27Gln showed higher PWV and CTR, but lower LVMI compared with the other combined genotypes. Patients with Ser49Ser/Glu27Gln (n= 33) showed a hyperreactive hyperemia ratio, which meant improved vasodilator response.
Moreover, we performed haplotype-analysis for the β1ADR and β2ADR polymorphisms (Table 5 ). Although the number of patients with Gly49Gly/Arg389Arg in the β1ADR was very small ( n = 7), patients with this haplotype showed higher PWV and CTR compared with patients having the other haplotypes. Patients with the Arg16Arg/Glu27Gln haplotype in the β 2 ADR showed higher reactive hyperemia and LVMI.
Discussion
In this hospital-based study, the frequencies of five SNPs of three β ADRs in a patient population were determined. With respect to the two SNPs of β 1 ADR SNPs, the data for the Ser49Gly SNPs were not significantly different from those in a report from Sweden ( 27 ) , and Arg389Gly also exhibited the same percentage of SNPs as reported by a Japanese group ( 14 ) . In addition, the previously reported frequencies of two β 2 ADR SNPs, Gly16Arg and Glu27Gln, in a Japanese ( 28 ) and a Taiwanese ( 29 ) cohort were identical to the respective frequencies determined here. Finally, the frequency of Trp64Arg for the β 3 ADR reflected the findings of another Japanese group ( 30 ) . Based on the accordance of our findings with these previous studies, our results would seem to be an accurate evaluation of the frequencies of these five β ADR SNPs.
The β 1 ADR are positioned at the cell membrane of cardiomyocytes. Subjects with the Gly allele in the Ser49Gly polymorphism have been reported to have a lower heart rate ( 20 ) , but in another study, the Ser49Gly β 1 ADR polymorphisms did not seem to exert a major effect on the changes in heart rate and blood pressure of patients with essential hypertension during 12 weeks of treatment with atenolol ( 31 ). The C allele of β 1 AR 1165C>G encodes arginine at amino acid 389, whereas the G allele encodes glycine. In vitro studies of isoproterenol stimulation showed that the Arg-389 receptors produce higher levels of adenylyl cyclase activity than the Gly-389 receptors ( 32 ), resulting in enhanced cardiac sensitivity to catecholamines. In another study, the Gly16 and Glu27 polymorphisms in the β 2 ADR were associated with sympathetic overactivity, as reflected by high plasma norepinephrine levels ( 33 ) . In a study by Eisenach et al ., dietary sodium restriction blunted the increase in nitric oxide-mediated, β 2 ADR responsiveness in Gly16 homozygotes of the forearm following administration of normal dietary sodium, while baseline CO decreased and peripheral resistance were increased by the sodium restriction (34) . In male twins with highly similar genetic and environmental backgrounds, the Arg64 variant of the β3ADR polymorphism was found to be associated with insulin resistance and higher post-prandial hyperglycemia (35) .
In the previous studies, PWV was shown to be effective as an index of stiffened vessels and decreased compliance, which was strongly correlated with increased pulse pressure and aging, and NTG-induced hyperemia was considered to be a marker of endothelium-independent vasodilatation. This type of dilatation was considered to be medial smooth-muscle-cell-related vasodilatation. Previous reports have suggested that βADR mediates smooth muscle relaxation in the small resistance arteries and large conduit arteries (36) . In the present study, we only found an association between a genetic polymorphism in Ser49Gly of the β1ADR and the aortic stiffness as measured by PWV, and the Gly49Gly genotype showed a genetic association with NTG-induced hyperemia. Although functional analysis is required, Ser49Gly polymorphism of the β1ADR might influence arterial functional changes.
We also performed a combined analysis of the various polymorphism and haplotype results. This analysis revealed several statistically significant parameters in regard to the intermediate phenotype; however, we were unable to reach a definitive conclusion about these findings due to the small number of subjects studied. Although the present study had several limitations, it nonetheless underscored the possibility of a relationship between βADR SNPs and intermediate phenotypes, such as functional arterial changes and cardiac remodeling. Clinically, these findings might be important when considering the relationship between autonomic nervous system responses and hypertensive complications in patients with essential hypertension.
Study Limitations
Our study was a hospital-based, cross-sectional research that included patients with essential hypertension and had several limitations. First, a large number of clinical studies will be required to analyze the relationship between polymorphisms and intermediate phenotypes, such as LVH and arterial stiffness. Moreover, for the haplotype and combined analyses, the number of subjects in this study was too small to provide definitive results, and the statistical power was low. Second, subjects showed heterogeneity of clinical background, which influences cardiovascular events, with some patients having taken medicines and some patients having been sick for a longer or shorter period of time. Third, to strictly evaluate the genetic influences of βADR genes, a cohort study would be much better. Fourth, as our study was a hospital-based study, there may have been a selection-bias. In general, it is better to use a population-based study for analyzing genetic influences, in order to avoid such a bias. Nonetheless, although there were several important limitations and although a larger, population-based cohort study might be required, the present study showed an association between βADR gene polymorphisms and arterial or cardiac remodeling in hypertensive patients.
